Hologic finalizes acquisition of DRC

Article

Hologic finalizes acquisition of DRCBone densitometer firm Hologic has completed its purchase of Direct Radiography from SDI Holding, the parent company of Agfa subsidiary Sterling Diagnostic Imaging. The deal was valued at about $20 million,

Hologic finalizes acquisition of DRC

Bone densitometer firm Hologic has completed its purchase of Direct Radiography from SDI Holding, the parent company of Agfa subsidiary Sterling Diagnostic Imaging. The deal was valued at about $20 million, consisting of $7 million in cash and around 1.9 million shares of Hologic common stock. The purchase amount decreased sharply from the initial agreement, which was valued at about $30 million.

Hologic was able to get some price concessions in exchange for a speedy closing, said David Ellenbogen, Hologic chairman and CEO.

As a result of the acquisition, Hologic receives about 90 employees, a 168,000-square-foot research, development, manufacturing, and administrative site in Newark, DE, and 26 U.S. patents, as well as a number of foreign ones.

Hologic plans to market DRC’s DirectRay digital radiography technology via a number of channels, including OEM opportunities. Discussions with several potential OEM clients are under way, Ellenbogen said.

The company also will participate in the retrofit sector, equipping recently purchased traditional x-ray rooms with its DirectRay detectors to pave the way for PACS, he said. In addition to the firm’s first retrofit site at Brooke Army Medical Center in Fort Sam Houston, TX, (PNN 2/99), DRC has installed a retrofit at an undisclosed location.

Finally, Bedford, MA-based Hologic will continue DRC’s direct sales efforts with its traditional iiRAD systems. In future development plans, Hologic expects to bring DirectRay technology suitable for fluoroscopy and mammography applications to market. Commercialization of these products would not occur for at least a year, however, Ellenbogen said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.